Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities Based on Occupational Health Care Registry in Finland: an Observational Retrospective Mirror-image Study (REFI)
Latest Information Update: 25 May 2022
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Aug 2021 New trial record
- 22 Jun 2021 Results presented at the 7th Congress of the European Academy of Neurology